Cathleen McCabe, MD, discusses VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, and how it provides opportunities for patients looking for spectacle independence.

Cathleen McCabe sits down with Sheryl Stevenson of Modern Retina to discuss the recently FDA-approved drops, VUITY.

At AAO 2021, her presentation entitled, “GEMINI 1 and 2 pooled Phase 3 safety and efficacy: AGN-190584 primary and key secondary endpoints,” discussed the finer points of the clinical trial that led to VUITY’s early approval.

Allergan, a subsidiary of AbbVie, announced on October 29, 2021, that the US Food and Drug Administration (FDA) has approved pilocarpine HCl Ophthalmic Solution 1.25% for the treatment of adult patients with presbyopia.

Pilocarpine HCl ophthalmic solution 1.25% is the first and only approved eye drop to treat age-related blurry near vision.

The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.

Please click the link below to watch the video.

Read more: https://www.ophthalmologytimes.com/view/fda-approved-eye-drops-target-presbyopia-patients

Source: Ophthalmology Times